TEAD3

Across TCGA pan-cancer cohorts, TEAD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TEAD3 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TEAD3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TEAD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where TEAD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.944	0.665	.006	23	view →
LUAD	DFS	Tertile	III,IV	0.566	0.976	.008	22	view →
PDAC	OS	Tertile	III,IV	0.864	0.413	.019	8	view →
HNSC	DFS	Tertile	III,IV	0.627	1.000	.045	2	view →
CCRCC	DFS	Median	II,III,IV	0.485	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TEAD3–LSCC (OS)

Open the LSCC breakdown →